Altamira Therapeutics (CYTOF) AI Stock Analysis

• Market Cap: $221.12K
• Dividend Yield: N/A
• Average Volume (3M): 7.08K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 77
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 3,778,524
• 10 Day Avg. Volume: 6,743
• 30 Day Avg. Volume: 7,080
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 23.70
• Price to Cash Flow (P/CF): N/A
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Altamira Therapeutics exhibits significant financial and operational challenges, typical of early-stage biotechnology firms, with notable weaknesses in revenue generation and cash flow management. Technical indicators denote a strong bearish trend, with the stock trading well below key moving averages and showing oversold conditions. The lack of valuation metrics and earnings call insights adds to the uncertainty, leading to a cautious and low overall stock score.

Altamira Therapeutics Business Overview & Revenue Model

Company Description

Altamira Therapeutics (CYTO) is a biopharmaceutical company focused on developing and commercializing RNA-based therapeutics. The company operates in the biotechnology sector, leveraging its proprietary technology platforms to create innovative treatments for various diseases, including inner ear disorders, nasal and allergy conditions, and other RNA-targeted therapies. Altamira aims to address unmet medical needs by advancing its pipeline of novel products through clinical development and regulatory approval.

How the Company Makes Money

Altamira Therapeutics primarily generates revenue through the development and commercialization of its RNA-based therapeutic products. The company may earn income from licensing agreements, partnerships, and collaborations with other pharmaceutical companies to co-develop or market its therapies. Additionally, Altamira could secure funding through government grants, research collaborations, and milestone payments tied to the successful progression of its drug candidates through clinical trials. As its products gain regulatory approval and enter the market, sales from these therapies would also contribute to the company's revenue streams. Strategic alliances and potential royalties from licensed technologies further enhance Altamira's earnings potential.

Altamira Therapeutics Financial Statement Overview

Summary

Altamira Therapeutics is facing financial challenges typical of early-stage biotechnology companies, marked by negative earnings, operational inefficiencies, and cash flow difficulties. While there is an improvement in equity, the company continues to struggle with revenue generation and cash management. These factors suggest a high-risk profile with potential needs for operational restructuring or additional funding.

Income Statement

Altamira Therapeutics has been experiencing declining revenue, with a significant revenue drop from 2020 to 2023. The company has consistently reported negative net income, resulting in poor net profit margins. EBIT and EBITDA margins are also negative, indicating operational inefficiencies and challenges in managing costs relative to revenue.

Balance Sheet

The company has demonstrated significant improvement in equity from a negative position in 2022 to a positive value in 2023, which is a positive sign. However, the debt-to-equity ratio remains concerning due to high liabilities relative to equity in earlier years. The equity ratio remains weak, reflecting limited asset backing by equity.

Cash Flow

Altamira Therapeutics has faced persistent negative free cash flow, indicating ongoing cash outflows exceeding cash inflows. Additionally, the operating cash flow to net income ratio is negative, suggesting that the company struggles to convert income into cash, which could affect liquidity.

Breakdown
TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
-353.22K	0.00	305.62K	63.88K	174.47K	-56.00K
	Gross Profit
-691.22K	0.00	-1.14M	-2.18M	174.47K	-56.00K
	EBIT
-1.79M	-5.92M	-26.13M	-17.10M	-5.28M	-7.26M
	EBITDA
2.02M	-1.35M	-17.64M	-6.72M	-5.26M	-7.24M
	Net Income Common Stockholders
-15.83M	-7.27M	-26.53M	-17.39M	-8.20M	-6.63M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
49.57K	617.41K	15.39K	984.19K	11.26M	1.38M
	Total Assets
6.20M	7.69M	6.30M	18.84M	20.80M	9.23M
	Total Debt
3.35M	99.66K	6.33M	575.74K	523.92K	0.00
	Net Debt
3.30M	-517.75K	6.32M	-408.45K	-10.73M	-1.38M
	Total Liabilities
8.03M	1.24M	14.62M	6.13M	4.03M	3.19M
	Stockholders Equity
-1.82M	6.46M	-8.31M	12.70M	16.77M	6.04M
Cash Flow		Free Cash Flow
-10.81M	-11.51M	-10.83M	-17.00M	-7.16M	-11.41M
	Operating Cash Flow
-10.81M	-11.51M	-8.68M	-13.67M	-4.84M	-8.39M
	Investing Cash Flow
-608.03K	1.44M	-2.14M	-3.51M	-2.31M	-3.00M
	Financing Cash Flow
10.99M	10.62M	9.83M	6.61M	16.96M	7.38M

Altamira Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.06
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CYTOF, the sentiment is Negative. The current price of 0.06 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.11, and below the 200-day MA of 0.55, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 41.29 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CYTOF.

Altamira Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TGTX	58 Neutral	$5.87B	267.55	12.21%	―	40.80%	100.62%
Sector *	48 Neutral	$6.36B	1.14	-49.00%	2.63%	17.14%	1.39%
AVDL	46 Neutral	$657.08M	―	-60.44%	―	504.79%	74.24%
KPTI	36 Underperform	$32.49M	―	41.08%	―	-0.55%	49.85%
CYTOF	25 Underperform	$221.12K	―		―	―	―